Cardiol Therapeutics Inc. (TSX: CRDL; OTCQX: CRTPF) is focused on producing the purest pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx, is designed to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically produced, cGMP certified, and does not contain any THC. The Company plans to commercialize CardiolRx during 2019 in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America.
In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit www.cardiolrx.com.
- Science & Technology
- Therapeutic Targets
- Product Pipeline
- Investor Information
- Corporate Presentation
Latest Stock Info
Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II/III COVID-19 Trial
Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition -- SECFilings.com
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)
Orphan Drug Designation Is Proven Path for CBD -- SECFilings.com
Heart Health and COVID-19: Fighting Inflammation May be Key -- SECFilings.com
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
David Elsley Files Early Warning Report for Cardiol Therapeutics
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
Cardiol Therapeutics Reports 2020 AGM Results
Sorry, we weren't able to find any articles. Click here to return to our homepage.